On the additive artificial intelligence-based discovery of nanoparticle neurodegenerative disease drug delivery systems

• Shan He,
• Julen Segura Abarrategi,
• Harbil Bediaga,
• Sonia Arrasate and
• Humberto González-Díaz

Beilstein J. Nanotechnol. 2024, 15, 535–555, doi:10.3762/bjnano.15.47

• resulting N2D3Ss shown in Figure 5 involve twenty different NDDs. The first ten are 1 = clozapine, 2 = galantamine, 3 = levodopa, 4 = apomorphine, 5 = fiduxosin, 6 = beagacestat, 7 = memoquin, 8 = mesodihydroguairetic acid, 9 = tarenflubil, and 10 = huperzine A. The other ten NDDs are 11

Key for crossing the BBB with nanoparticles: the rational design

• Sonia M. Lombardo,
• Marc Schneider,
• Akif E. Türeli and
• Nazende Günday Türeli

Beilstein J. Nanotechnol. 2020, 11, 866–883, doi:10.3762/bjnano.11.72

• the drugs or to use prodrugs. One example of a prodrug is levodopa, a prodrug of dopamine used for the treatment of Parkinson’s disease. However, these options are not always possible depending on the structure of the molecule. Another possibility to increase drug delivery through the BBB is to

Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes

• Julia M. Tan,
• Jhi Biau Foo,
• Sharida Fakurazi and
• Mohd Zobir Hussein

Beilstein J. Nanotechnol. 2015, 6, 243–253, doi:10.3762/bjnano.6.23

• , 43400 UPM Serdang, Selangor, Malaysia 10.3762/bjnano.6.23 Abstract This work explores the potential use of commercially obtained, carboxylated, single-walled carbon nanotubes (SWCNT–COOH) as nanocarriers for the antiparkinson drug, levodopa (LD). The resulting nanohybrid was characterized using

• carbon nanotubes; levodopa; MTT assay; nanomedicine; Parkinson’s disease; PC12 cells; sustained release; Introduction Over the past few years, the revolutionary development of nanomedicine has emerged as one of the most prominent research areas in biomedical science. This interdisciplinary technology is

• -(3,4-dihydroxyphenyl)propanoic acid (levodopa) still remains the gold standard for the treatment of PD for symptomatic relief [12]. Now entering into its fourth decade of clinical use, levodopa (LD, the amino acid precursor of dopamine) is the most effective, widely prescribed, oral administered drug